Enlivex Therapeutics (ENLV) Earnings Analysis
Enlivex Therapeutics (ENLV) next reports earnings on 2026-09-04, consensus EPS -0.3 USD. Last quarter (2026-03-30) it missed with EPS -3.45 USD vs -0.45 USD est (-666.7%). It has beaten estimates in 6/8 recent quarters (75%). Trailing P/E 0.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ENLV next report earnings?
| Next earnings date | 2026-09-04 |
|---|---|
| Consensus EPS estimate | -0.3 USD |
| Revenue estimate | n/a |
ENLV earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-30 | -3.45 USD | -0.45 USD | -666.7% | Miss |
| 2026-03-25 | 410.25 USD | -1.2945 USD | +31791.8% | Beat |
| 2025-12-05 | -0.117 USD | -1.8 USD | +93.5% | Beat |
| 2025-09-05 | -2.181 USD | -2.4 USD | +9.1% | Beat |
| 2025-06-13 | -2.30175 USD | -2.4 USD | +4.1% | Beat |
| 2025-04-04 | -0.24 USD | -2.4 USD | +90% | Beat |
| 2024-11-28 | -0.12 USD | -2.4 USD | +95% | Beat |
| 2024-09-06 | -2.4 USD | -2.25 USD | -6.7% | Miss |
Beat rate: 6/8 (75%) over reported quarters with consensus data.
ENLV valuation and analyst view
| Trailing P/E | 0.01 |
|---|---|
| Trailing EPS | 407.81 USD |
| Price / book | 0.01 |
| Dividend yield | 0.00% |
| Market cap | 0.08B |
| Analyst consensus | Buy (3 buy / 1 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Enlivex Therapeutics (ENLV)'s next earnings date?
Enlivex Therapeutics is next scheduled to report on 2026-09-04, with a consensus EPS estimate of -0.3 USD.
Did ENLV beat earnings last quarter?
In its 2026-03-30 report, ENLV posted EPS of -3.45 USD versus a -0.45 USD estimate — a miss of 666.7%.
What is ENLV's earnings track record?
Over the last 8 reported quarters with consensus data, ENLV beat estimates 6 times (75%).
What is ENLV's current P/E ratio and EPS?
ENLV trades at a trailing P/E of 0.01 on trailing EPS of 407.807546925686 USD.
What do analysts rate ENLV?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell).